04:09 AM EDT, 08/20/2025 (MT Newswires) -- Myriad Genetics ( MYGN ) has formed a collaboration with liquid biopsy company Angle, the latter said Wednesday.

Under the collaboration, Angle's research and development team will process blood samples from cancer patients using the Parsortix system for downstream molecular analysis. The results will be compared with matched patient tissue samples using Myriad Genetics' ( MYGN ) tissue-based assay, Angle said.